MetAlert (MLRT) Eliminates Toxic Debt, Launches New Medical Device Products

(NEW YORK) -- Ludlow Research updated its research opinion on MetAlert, Inc. (OTC: MLRT), a pioneer in location sensitive health monitoring devices and wearable technology products for remote patient monitoring, based on elimination of toxic debt and launch of new medical device products for cognitive markets.

Read recent Analyst Brief conducted Jan. 05, 2023
https://ludlowresearch.com/mlrt-analyst-brief-012023/

REPORT HIGHLIGHTS

- Expansion of medical devices for aging and autism market
- Ramp-up in SmartSole unit production to fulfill backorders
- Elimination of toxic convertible debt

SUMMARY

Toxic debt, or variable convertible notes, are a form of debt, which sometimes convert at deep discounts to market price, and are major contributors to shareholder dilution and price instability for small issuers.

In recent months, MetAlert extinguished all of their toxic convertible notes from their balance sheet, which should now provide increased stability to their public float.

The influx of new chips in Q4 2022 should significantly increase production of SmartSole units in early 2023. This ramp-up in production should help fulfill backorders currently in place, and increase revenues in the coming months.

The elimination of toxic debt, improved guidance to their NFC operations, and launch of new medical devices geared towards the geriatric and autism healthcare markets now places the company in a much healthier position going forward into 2023.

About MetAlert

MetAlert, Inc. (OTC: MLRT) is a pioneer in smart, mobile, and wearable tracking and recovery location-based solutions, supported through a proprietary iot enterprise monitoring platform and intellectual property portfolio. The Company offers a global end-to-end solution of hardware, software and connectivity and develops two-way GPS tracking technologies, which seamlessly integrate with consumer products and enterprise applications, utilizing the latest in miniaturized, low power consumption GPS, Cellular, RF, NFC, and BLE technology, enabling subscribers to track in real time the whereabouts of people or high value assets. Known for its game-changing and award-winning patented GPS SmartSole – think Dr. Scholl’s meets LoJack, the world’s first visible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism and traumatic brain injury. MetAlert´s business model is built around technology innovation and the Company holds dozens of patents, with many issued patents in the area of GPS tracking. The Company has international distributors servicing customers across the globe with subscribers in over 40 countries, and is a U.S. Military Government contractor. Other customers include public health authorities and municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes, and consumers. www.MetAlert.com

Disclosures and Disclaimer:

THE MATERIAL HEREIN DOES NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY JURISDICTION WHERE OR TO ANY PERSON TO WHOM IT WOULD BE UNAUTHORIZED OR UNLAWFUL TO DO SO.

This reports contains certain statements that may be deemed “forward-looking” statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by law, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Ludlow Research (“Ludlow”), and its parent company Ludlow Consulting, LLC, are not registered broker-dealers or investment advisers with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”), or any state securities regulatory authority.

Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Ludlow does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. Ludlow, its affiliates, or directors, may or may not hold a position in the above security from time to time, and investors are encouraged to consider this as a possible conflict of interest when reviewing this information. In Compliance with SEC Rule 17B Ludlow was compensated one thousand dollars for research report, and holds business relationships through affiliate company, and thus should be considered a conflict of interest when reviewing this information. Investments is speculative ‘penny stocks’, as defined by the SEC, may involve a high degree of risk.

INVESTORS ARE HIGHLY ENCOURAGED TO CONSULT WITH A FINANCIAL ADVISOR BEFORE MAKING ANY AND ALL INVESTMENT DECISIONS.